研发生产率挑战:改变制药生态系统
Alexander Schuhmacher1, Oliver Gassmann2, Sebastian Kwisda3
1Technische Hochschule Ingolstadt, Germany; University of St Gallen, Switzerland.
Drug discovery today
|October 9, 2025
概括
药品研发生产率下降对整个行业产生了影响,迫使进行重大变革. 大型制药公司面临重大挑战,而其他生物制药生态系统参与者可能会受益.
科学领域:
- 制药行业 制药行业 制药行业
- 生物技术是生物技术.
- 药物开发 药物开发
背景情况:
- 过去二十年来,制药研发生产率持续下降.
- 这对行业结构和战略产生了深远的影响.
- 领先公司调整研发模式.
研究的目的:
- 分析研发生产率下降的影响.
- 检查行业演变为生物制药生态系统的情况.
- 评估对不同利益相关者的后果.
主要方法:
- 对行业趋势的定性分析.
- 审查研发领域的战略调整.
- 检查利益相关者的相互依存关系.
主要成果:
- 工业发展成为一个复杂的生物制药生态系统.
- 大型制药公司受到生产率问题的影响最大.
- 其他利益相关者经历了各种各样的影响,有些是有益的.
结论:
- 研发生产率对于大型制药公司的竞争力至关重要.
- 生物制药生态系统结构是对研发挑战的回应.
- 利益相关者价值在不断变化的环境中分布不均.
相关概念视频
Biopharmaceutical Factors Influencing Drug Product Design: Overview
233
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
233
Drug Discovery: Overview
11.0K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
11.0K
Drug Products: Biologics, Biosimilars and Interchangeables
233
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
233
Biopharmaceutics and Pharmacokinetics: Overview
3.3K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
3.3K
Prodrugs
4.0K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
4.0K
Drug Administration and Therapy Phases: Overview
1.3K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.3K


